



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application	
Inventor(s)	
for	
Title of invention	
	OR
in re application of: Poopthay Kathir	gamanathan et al.
Application No.:XX 10/549,430 Filed: September 15, 2005 For: Electroluminescent Boron C	Group Art Unit: Examiner: Complexes
Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
WITHIN THREE	MATION DISCLOSURE STATEMENT MONTHS OF FILING OR OFFICE ACTION (37 C P. 8. 1.97(b))
WITHIN THREE BEFORE MAILING OF FIRST CERTIFICATION UND (When using Express Mell, the	
WITHIN THREE BEFORE MAILING OF FIRST CERTIFICATION UND (When using Express Mell, the	MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) ER 37 C.F.R. §§ 1.8(a) and 1.10* Express Mail later number is mandatory; il certification is optional.)
WITHIN THREE BEFORE MAILING OF FIRST CERTIFICATION UND (When using Express Mail, the Express Mail hereby certify that, on the date shown below, t	MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) ER 37 C.F.R. §§ 1.8(a) and 1.10° be Express Meil label number is mandatory; of certification is optional.) this correspondence is being:
WITHIN THREE BEFORE MAILING OF FIRST CERTIFICATION UND (When using Express Med, the Expre	MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) ER 37 C.F.R. § 1.8(a) and 1.10° Express Mail label number is mandatory; it certification is optional.) his correspondence is being: MAILING to in an envelope addressed to Commissioner for Patenta, P.O. 37 C.F.R. § 1.10°
WITHIN THREE BEFORE MAILING OF FIRST CERTIFICATION UND (When using Express Med, the Expre	MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) ER 37 C.F.R. § 1.5(a) and 1.10* 5 Express Mail laber number is mandatory; il certification is optional.) his correspondence is being: MAILING ce in an envelope addressed to Commissioner for Patenta, P.O. 37 C.F.R. § 1.10 * as "Express Mail Post Office to Addressee"
WITHIN THREE BEFORE MAILING OF FIRST CERTIFICATION UND (When using Express Med, the Expre	MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) ER 37 C.F.R. § 1.8(a) and 1.10° Express Mail label number is mandatory; it certification is optional.) his correspondence is being: MAILING to in an envelope addressed to Commissioner for Patenta, P.O. 37 C.F.R. § 1.10°
WITHIN THREE BEFORE MAILING OF FIRST CERTIFICATION UND (When using Express Med, the Expre	MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) ER 37 C.F.R. § 1.8(a) and 1.10° Express Mail label number is mandatory; it certification is optional.) his correspondence is being: MALING to in an envelope addressed to Commissioner for Patenta, P.O. 37 C.F.R. § 1.10° a "Express Mail Post Office to Addressee" Mailing Label No
WITHIN THREE BEFORE MAILING OF FIRST CHARLING OF FIRST CHARLING OF FIRST (When using Express Med, the Express Med, the Express Med to the shown below, to the date shown below, to deposited with the United States Postal Servic Box 1450, Aboxandria, VA 22313-1450 37 C.F.R. § 1.8(a) With sufficient postage as first class mail.	MONTHS OF FILING OR OFFICE ACTION (37 C.F.R. § 1.97(b)) ER 37 C.F.R. § 1.8(a) and 1.10° Express Mail label number is mandatory; it certification is optional.) his correspondence is being: MALING to in an envelope addressed to Commissioner for Patenta, P.O. 37 C.F.R. § 1.10° a "Express Mail Post Office to Addressee" Mailing Label No

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.6 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.71) or facetimite transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

(type or print name of person certifying)

(Transmittal of Information Disclosure Statement Within Three Months of Filing or Before Mailing of First Office
Action (6-3)—page 1 of 3)

- (1) Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.
- (2) Each U.S. patent application publication listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication date.
- (3) Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.
- (4) Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or petent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.
- (5) Each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages of the publication, date, and place of publication.

WARNING: No extension of time can be had under 37 C.F.R. § 1.136 (a) or (b) for filing an IDS. 37 C.F.R. § 1.97ff.

NOTE: The "filling date of a national application" under 37 C.F.R. § 1.97(b) has two possible meanings. Where the filling is a direct one to the United States Patent & Trademark Office, the filling is defined in 37 C.F.R. § 1.53(b) as "the date on which: (f) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41" 37 C.F.R. § 1.97(b)(f). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and leas required by § 5.U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (f) the basic national fee; (2) a copy of the international application, unless already eart by the International Bureau, and optionally an English translation into English if made in another language; and, also optionally (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or doctaration; and (5) a translation into English if and on the another language; (4) an oath or doctaration; and (5) a translation into English if and on the produce of the international preliminary examination report, if such annows were made in another language. The optional items must be submitted later, with surcharges, 37 C.F.R. § 1.79(b)C.R.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last 37 C.F.R. § 1.97(b).

- NOTE: "No cartification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been malled if the disclosure statement is delayed until after three months from filing."
- NOTE: "An Information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a milling if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An Office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39). See also § 609. M.P.E.P. &th Edition.
- NOTE: "The term 'national application' includes continuing applications (continuations, divisions, continuations-in-part) so three-months will be measured from the actual filing date of an application as opposed gift to the effective date of a continuing application." Notice of April 20, 1982 (1198 O.G. 37-41, 39).

Reg. No.: 26,336

Customer No :

Tel. No.: (978) 470-0990

NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formed or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filled on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filled prior to July 1." Notice of April 20, 1992 (1193 D.G. 37-41, 39), 37-41, 39).

WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. \$ 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63). But see § 103(b) and (c), limited suspension of action in a continued prosecution application (CPA) filed under § 1.53(d) and in a request for continued examination (FCC) under § 1.114.

SIGNATURE OF PRACTITIONER

David Silverstein

(type or print name of practitioner)

Andover-IP-Law

P.O. Address

44 Park Street, Suite 300 Andover, MA 01810

Docket No. LUC-016 U.S. Ser. No. 10/549,430

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Attached is form PTO-1449A listing prior art materials referenced in the Specification of this application.

A copy of each of the non-U.S. patent items listed in PTO-1449A is enclosed.

Respectfully submitted,

David Silverstein

Registration Number 26,336 Attorney for Applicants

Andover-IP-Law 44 Park Street, Suite 300

Andover, MA 01810 Telephone: (978) 470-0990 Facsimile: (978) 470-0993